239 related articles for article (PubMed ID: 10856450)
1. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
Gupta P; Butler P; Shepperson NB; McHarg A
Eur J Pharmacol; 2000 Jun; 398(1):73-81. PubMed ID: 10856450
[TBL] [Abstract][Full Text] [Related]
2. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.
Gupta P; Brown D; Butler P; Ellis P; Grayson KL; Land GC; Macor JE; Robson SF; Wythes MJ; Shepperson NB
Br J Pharmacol; 1995 Nov; 116(5):2385-90. PubMed ID: 8581273
[TBL] [Abstract][Full Text] [Related]
3. Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity.
Willems E; De Vries P; Heiligers JP; Saxena PR
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):212-9. PubMed ID: 9750007
[TBL] [Abstract][Full Text] [Related]
4. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
5. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model.
Knyihár-Csillik E; Tajti J; Csillik AE; Chadaide Z; Mihály A; Vécsei L
Eur J Neurosci; 2000 Nov; 12(11):3991-4002. PubMed ID: 11069595
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor.
Gupta P; Scatchard J; Napier C; McHarg A; Wallis R
Eur J Pharmacol; 1999 Feb; 367(2-3):283-90. PubMed ID: 10079003
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological, pharmacokinetic and clinical profile of eletriptan (Relpax), a new triptan for migraine].
Omote M
Nihon Yakurigaku Zasshi; 2003 Jul; 122(1):93-101. PubMed ID: 12843576
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.
Johnson DE; Rollema H; Schmidt AW; McHarg AD
Eur J Pharmacol; 2001 Aug; 425(3):203-10. PubMed ID: 11513839
[TBL] [Abstract][Full Text] [Related]
9. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater.
Yu XJ; Cutrer FM; Moskowitz MA; Waeber C
Neuropharmacology; 1997 Jan; 36(1):83-91. PubMed ID: 9144644
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats.
Shepherd SL; Williamson DJ; Beer MS; Hill RG; Hargreaves RJ
Neuropharmacology; 1997; 36(4-5):525-33. PubMed ID: 9225277
[TBL] [Abstract][Full Text] [Related]
11. Unravelling the pharmacological profile of the canine external carotid vasodilator '5-HT1-like' receptors: coexistence of sympatho-inhibitory 5-HT1B and postjunctional 5-HT7 receptors.
Villalón CM; Sánchez-López A; Centurión D; Saxena PR
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):73-80. PubMed ID: 11191839
[TBL] [Abstract][Full Text] [Related]
12. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.
Buzzi MG; Moskowitz MA; Peroutka SJ; Byun B
Br J Pharmacol; 1991 Jun; 103(2):1421-8. PubMed ID: 1653072
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs.
Parsons AA; Parker SG; Raval P; Campbell CA; Lewis VA; Griffiths R; Hunter AJ; Hamilton TC; King FD
J Cardiovasc Pharmacol; 1997 Jul; 30(1):136-41. PubMed ID: 9268233
[TBL] [Abstract][Full Text] [Related]
14. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
15. Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.
Muñoz-Islas E; Gupta S; Jiménez-Mena LR; Lozano-Cuenca J; Sánchez-López A; Centurión D; Mehrotra S; MaassenVanDenBrink A; Villalón CM
Br J Pharmacol; 2006 Sep; 149(1):82-91. PubMed ID: 16880765
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Napier C; Stewart M; Melrose H; Hopkins B; McHarg A; Wallis R
Eur J Pharmacol; 1999 Mar; 368(2-3):259-68. PubMed ID: 10193663
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels.
van den Broek RW; MaassenVanDenBrink A; de Vries R; Bogers AJ; Stegmann AP; Avezaat CJ; Saxena PR
Eur J Pharmacol; 2000 Oct; 407(1-2):165-73. PubMed ID: 11050304
[TBL] [Abstract][Full Text] [Related]
18. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Williamson DJ; Hill RG; Shepheard SL; Hargreaves RJ
Br J Pharmacol; 2001 Aug; 133(7):1029-34. PubMed ID: 11487512
[TBL] [Abstract][Full Text] [Related]
19. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026
[TBL] [Abstract][Full Text] [Related]
20. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.
Muñoz-Islas E; Lozano-Cuenca J; González-Hernández A; Ramírez-Rosas MB; Sánchez-López A; Centurión D; Maassenvandenbrink A; Villalón CM
Eur J Pharmacol; 2009 Aug; 615(1-3):133-8. PubMed ID: 19460365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
